Document is current
Any future updates will be listed below
-
Authors
Schlachetzki, Zinayida
Langford, Oliver https://orcid.org/0009-0006-8951-1326
Zammit, Matthew D. https://orcid.org/0000-0001-8966-8397
Donohue, Michael C. https://orcid.org/0000-0001-6026-2238
Zhou, Xiaoyu
Sukreet, Sonal
Abdel-Latif, Sara
Braunstein, Joel B.
Rissman, Robert A.
Rafii, Michael S. https://orcid.org/0000-0003-2640-2094
- License Information
-
More Information
Article History
Received: 12 December 2025
Accepted: 27 May 2026
First Online: 2 June 2026
Competing interests
: M.S.R. has NIH Grants: R01AG073979; R61AG066543; R33AG066543; U19AG068054. His institution has contracts with Eisai and Eli Lilly. He serves as consultant to AC Immune and Ionis. He serves on the Data Safety Monitoring Board/Scientific Advisory Boards for Aerska, Alnylam, Alzheon, Biohaven, Embic, Otsuka, Positrigo, Recall Therapeutics. M.D.Z. received honoraria from the University of Southern California Alzheimer’s Therapeutic Research Institute and LuMind IDSC Foundation. M.C.D. reported personal fees from Roche (consultant) and Johnson & Johnson (spouse is full-time employee) outside the submitted work. J.B.B. is an employee of C2N Diagnostics. R.A.R. has received research support from the National Institutes of Health (NIH), the Alzheimer’s Association, American Heart Association, Eli Lilly and Eisai. All other authors declare no competing interests.
